INTRODUCTION {#S1}
============

Asthma, an allergic disorder that affects both adults and children, is a very heterogeneous and complex disease that involves multiple pathways and cellular components in its pathogenesis. Typically, allergic inflammation in the airway is characterized by a large increase in the numbers of immune cells such as mast cells, basophils, neutrophils, eosinophils, and innate lymphoid cells, and a skewed Th2 cytokine response with increases in IL-4, IL-5, and IL-13 ([@R1], [@R2]). Additionally, allergen-specific Immunoglobulin E (IgE) antibody is consistently present in human nasal washings and bronchoalveolar lavage (BAL) fluid and is markedly increased during human allergic rhinitis and bronchial asthma ([@R3], [@R4]). These observations are in agreement with the fact that IgE-producing plasma cells are present in the nasal mucosa of allergic individuals, where B cells locally synthesize IgE, as well as in inflamed lungs ([@R5], [@R6]). Furthermore, allergen-specific plasma cells can persist in lymphatic organs, secreting IgE over several years even in the absence of allergen. In addition, viral-specific IgE has been suggested to play a role in virus-mediated exacerbation of asthma ([@R7]).

IgE antibody is essential in development of airway inflammation and airway hyper-responsiveness (AHR) because it links multivalent allergen binding to the high-affinity IgE receptor (FcεRI) on the surface of sensitized mast cells and basophils, which thereby results in a cascade of enhanced cellular events and the release of potent inflammatory mediators including histamine, prostaglandins, and leukotrienes. These mediators act on epithelial cells and smooth muscle cells and are responsible for clinical symptoms in allergic diseases ([@R1]). Allergen-loaded IgE can also activate antigen-presenting cells (APCs), which subsequently prime T-cell responses ([@R8]).

Unlike FcεRI, the role of FcεRII (CD23) in allergic inflammation remains elusive. CD23 is a type II membrane glycoprotein and its carboxyl-terminus consists of a C-type lectin head that binds IgE in a calcium-dependent manner ([@R9], [@R10], [@R11]). Although CD23 monomers display realtively low-affinity (Ka ≈ 10^6^ --10^7^) for IgE, the membrane-bound CD23 can form a trimer allowing CD23 to bind IgE with high affinity (Ka ≈ 10^8^ --10^9^) ([@R9]--[@R12]). CD23 is expressed in a variety of cell types including B cells, activated T cells, eosinophils, monocytes, platelets, dendritic cells, and Langerhans cell, and possesses diverse binding partners such as integrins and CD21 ([@R9], [@R10]). Numerous studies have found that CD23 serves as a negative feedback regulator of IgE production ([@R9], [@R10], [@R13]). Moreover, CD23 and FcεRI α chain bind IgE in a mutually exclusive manner allowing IgE to function independently through these two receptors ([@R14]).

The epithelial lining of airways forms a physical barrier to inhaled environmental factors such as pathogens, allergens, and pollutants through the presence of apical tight junctions that seal the paracellular space ([@R15]). A transcellular pathway known as transcytosis mediates the transport of macromolecules across the polarized airway epithelium. Our recent study has shown that CD23 constitutively expressed on human AECs is capable of transporting IgE or IgE-antigen immune complexes (ICs) across human airway epithelial monolayers by transcytosis. Moreover, the cytokine IL-4 enhances transepithelial transport of IgE and of IgE-derived ICs across AECs ([@R16]).

Since AECs are the first cell layer to come into contact with inhaled allergens, we postulated that when transcytosed by AECs into the airway lumen, allergen-specific IgE captures airborne allergens and form ICs, which subsequently induce potent airway inflammatory immune responses. In this and previous studies, CD23 expression is observed in airway structural cells, predominantly epithelial cells ([@R16]). Using bone-marrow chimeras generated from WT and CD23 KOs, we discovered that structural cell CD23 expression is necessary and sufficient for the initiation and perpetuation of allergic inflammatory responses in airways. Most importantly, our results demonstrate that blocking CD23 function in the airway should be considered as a novel therapy for allergic asthma.

RESULTS {#S2}
=======

Mouse AECs express CD23 {#S3}
-----------------------

In order to examine the function of epithelial CD23 during allergic inflammation, we characterized CD23 expression in mouse AECs. To this end, we assessed protein expression in epithelial cells isolated from WT mouse nose, lung, and trachea. Using B3B4, a rat IgG2a Ab specific for mouse CD23, for detection a 49 kDa band was seen in each of these cell lysates as well as in lysates from splenic cells, but not CHO cells ([Fig. 1A+1B](#F1){ref-type="fig"}). Immunohistochemical analysis of WT mouse lung confirmed CD23 expression, using the spleen as a positive control and normal rabbit IgG staining as a negative control ([Fig. 1C](#F1){ref-type="fig"}, middle panel). When cytokeratin was used as a marker for epithelial cells, colocalization of CD23 and cytokeratin indicated the expression of CD23 in lung or tracheal epithelial cells ([Fig. S1](#SD1){ref-type="supplementary-material"}). Similar to human CD23, mouse CD23 exists in three isoforms ([@R17]). Using RT-PCR and sequencing of PCR products for confirmation, we found that CD23*b*, but not CD23*a*, mRNA was present in the mouse lung epithelial cell line LA4 ([Fig. S2](#SD1){ref-type="supplementary-material"}). In addition, exposure of LA4 cells to IL-4 resulted in enhanced expression of CD23*b* mRNA, but not CD23*a* or CD23bΔ5 (an isoform of CD23*b* that lacks exon 5) ([@R17]) ([Fig. S2](#SD1){ref-type="supplementary-material"}). Thus, similar to human AECs, mouse lung epithelial cells also express CD23 ([@R16]) indicating that epithelial cells are the major cell type highly expressing CD23 in airways.

CD23 transcytoses mouse IgE across the airway epithelial barrier {#S4}
----------------------------------------------------------------

Human CD23 bidirectionally transports IgE in polarized epithelial Calu-3 cells and in primary human tracheal/bronchial epithelial cells ([@R16]). To determine whether mouse CD23 is responsible for IgE transcytosis across AECs, we isolated primary tracheal epithelial cells from WT or CD23 KO mice. The absence of CD23 expression in CD23 KO mice was verified by both PCR and flow cytometry ([Fig. S3](#SD1){ref-type="supplementary-material"}). Cells were grown on transwell inserts (0.4-µm-pore size) to form polarized monolayers. Mouse IgE was added to either the apical or the basolateral chamber and cells were further incubated at 37°C for 2 h. As a negative control, mouse AECs was also incubated with IgE at 4°C for 2 h. Assessing transcytosis of IgE by ELISA, we found that IgE applied to either the apical ([Fig. 2A](#F2){ref-type="fig"}, *top panel*) or the basolateral ([Fig. 2A](#F2){ref-type="fig"}, *bottom panel*) chamber was transported across the epithelial monolayers in the opposite direction in WT, but not CD23 KO mice. No significant IgE transcytosis was detected in epithelial monolayers incubated at 4°C, ruling out the possibility of passive diffusion. To further confirm CD23-mediated IgE transcytosis across the mouse airway barrier from the apical (airway) epithelial surface to the basolateral (subepithelial and circulation) surface, we administered OVA-specific IgE (20 or 40 µg/ml) or PBS intranasally (i.n.) and collected serum at 4, 8, and 24 h to test for the presence of OVA-specific IgE by ELISA ([Fig. 2B](#F2){ref-type="fig"}, *top panel* and [Fig. S4A](#SD1){ref-type="supplementary-material"}). Mouse IgE was significantly elevated in sera of the WT mice compared to CD23 KO mice ([Fig. 2B](#F2){ref-type="fig"}, *top panel*) after both the 4 and 8 h inoculations. However, by 24 h the inoculated OVA-specific IgE was barely detectable in both WT and CD23 KO mice. To determine whether mouse IgE can also be transcytosed from the basolateral to apical surface, mouse OVA-specific IgE (20 or 40 µg/ml) or PBS was i.p. injected and BAL fluids were collected 8 h later to measure IgE by ELISA ([Fig. 2B](#F2){ref-type="fig"}, *bottom panel* and [Fig. S4B](#SD1){ref-type="supplementary-material"}). Similar to apical to basolateral transcytosis, a greater amount of IgE was detected in the BAL of WT mice than CD23 KO mice ([Fig. 2B](#F2){ref-type="fig"}, *bottom panel*). To further verify CD23-mediated IgE transcytosis *in situ*, WT mice were i.n. inoculated with IgE (20 µg/ml) or PBS and lung and trachea tissues were sampled for cryosectioning 20 min later. We detected IgE (green) in CD23-positive (red) cells ([Fig. 2C](#F2){ref-type="fig"}), but did not find any background staining of IgE in the PBS control group. In addition to CD23-positive epithelial cells, IgE (green) was also detected in the lung parenchyma underneath epithelial cells ([Fig. 2C](#F2){ref-type="fig"}), suggesting that the IgE Ab was transported by transcytosis. Similarly, CD23-positive cells in lung tissues also showed IgE and CD23 staining, which was absent in the PBS control group.

CD23 transcytoses IgE-allergen immune complexes (ICs) across the epithelial barrier {#S5}
-----------------------------------------------------------------------------------

Our previous study showed that human CD23 is capable of transporting ICs across primary human tracheal/bronchial epithelial cells *in vitro* ([@R16]). To assess this *in vivo*, we first generated IgE-OVA ICs *in vitro* and verified them by ELISA. Mice were i.n. administered IgE-OVA ICs or OVA alone, and sera were sampled 8 h later to test for the presence of OVA by ELISA. As shown in [Fig. 3A](#F3){ref-type="fig"}, a higher amount of OVA, representing OVA-IgE ICs, was detected in the sera of WT, but not CD23 KO mice. Furthermore, when OVA was administered alone it did not increase in the sera of either WT or CD23 KO mice ([Fig. 3A](#F3){ref-type="fig"}). To show trancytosis of ICs by CD23 *in situ*, we conducted immunohistochemical analysis that further revealed the co-localization of CD23 with IgE and OVA ([Fig. 3B](#F3){ref-type="fig"}, and [Fig. S5](#SD1){ref-type="supplementary-material"}). As expected, administration of PBS did not result in any significant staining ([Fig. S5](#SD1){ref-type="supplementary-material"}, *panel E*). Taken together, these data clearly demonstrate CD23-dependent transport of ICs across the mouse airway epithelial barrier.

### CD23 in airway epithelial cells promotes the development of airway allergic inflammation {#S6}

To examine the role of epithelial CD23 in allergic inflammation, we utilized an OVA-based allergy mouse model. First, Balb/c mice were sensitized with OVA or PBS (as a negative control) followed by three challenges with OVA. Treated WT mice exhibited responses characteristic of allergic inflammation with significantly higher levels of total and OVA-specific IgE, IL-4, and a greater number of total leukocytes and eosinophils in the BAL fluid and goblet cells of the lungs compared to control mice sensitized with PBS ([Fig. S6](#SD1){ref-type="supplementary-material"}). However, in order to induce inflammation without damaging the integrity of the airway epithelium and cause leakage of the airway lining, we reduced the number of OVA challenges to a single dose. This allowed us to examine the role of CD23-mediated transcytosis in the airway inflammatory response. First, to determine whether sensitization-induced inflammation has any effect on the level of CD23 expression in epithelial cells, lysates were prepared from the lung and tracheal epithelial cells of the sensitized or naive mice. Western blot analysis of the cell lysates showed that CD23 protein was significantly upregulated in AECs of the sensitized mice compared to naive mice ([Fig. 4A](#F4){ref-type="fig"} and [Fig. S7](#SD1){ref-type="supplementary-material"}). Hence, allergic inflammation augments CD23 expression in AECs.

Previous studies have shown that CD23 KO mice exhibit increased allergic inflammatory responses compared to WT mice ([@R18]--[@R20]). It is possible that deletion of CD23 in mice may result in structural changes in the lung; however, we were unable to detect any significant changes in inflammation, goblet cell hyperplasia, or peribronchial fibrosis in naive CD23 KO mice compared with naive WT mice ([Fig. S8](#SD1){ref-type="supplementary-material"}). Therefore, it is very likely that the increase in development of allergic inflammation in sensitized CD23 KO mice is directly associated with the absence of CD23 expression in hematopoietic cells. To compare the requirement for CD23 in hematopoietic cells and lung structural cells, especially epithelial cells, in mediating airway allergic inflammation we created bone marrow chimeric mice. Bone marrow cells were adoptively transferred between WT and CD23 KO mice to generate three different chimeras: WT/CD23KO, CD23KO/WT, and WT/WT. In WT/CD23KO mice (where WT bone marrow was injected into irradiated CD23 KO recipients), the airway structural cells are CD23 deficient, while hematopoietic cells express CD23. In CD23KO/WT mice (where CD23 KO marrow was injected into irradiated WT recipients) airway structural cells express CD23 while hematopoietic cells are CD23 deficient. As a control, bone marrow cells from WT mice were also transferred into irradiated WT mice, generating the WT/WT chimera with both airway structural and hematopoietic cells expressing the CD23 receptor. The success of hematopoietic cell repopulation was verified by assessing CD23^+^ B cells or total B cells in spleen, bone marrow, and mononuclear cells and T cells in spleen and lung using flow cytometry ([Fig. S9 and Fig. S10](#SD1){ref-type="supplementary-material"}). We did not detect any significant differences in the repopulated immune cells in the lung, spleen, or bone marrow of chimeric mice ([Fig. S9 and Fig. S10](#SD1){ref-type="supplementary-material"}).

First, to determine the role of CD23 expressed in AECs, WT/CD23KO, CD23KO/WT, and WT/WT chimeric mice were sensitized and challenged with OVA aerosol. Following the challenge, a significantly higher level of OVA antigen was detected in sera from WT/WT and CD23KO/WT mice compared to WT/CD23KO mice ([Fig. 4B](#F4){ref-type="fig"}). Next, we assessed whether OVA-specific IgE could be detected in the BAL fluid after OVA challenge and found that both WT/WT and CD23KO/WT mice had significantly increased levels of OVA-specific IgE in both BAL fluid and sera compared to WT/CD23KO mice ([Fig. 4C](#F4){ref-type="fig"}). Similarly, significantly higher levels of IL-4 were detected in both sera and BAL fluid of WT/WT and CD23KO/WT mice when compared to WT/CD23KO mice ([Fig. 4D](#F4){ref-type="fig"}). Although mice had equal numbers of total leukocytes in the BAL fluid, flow cytometric analysis revealed a significantly higher number of CD45^+^ CD11bhi/int CD11c^−^ Siglec-F^+^ eosinophils in the BAL fluid and CD45^+^ CD11bhi CD11c^−^ Siglec-F^+^ eosinophils in lung mononuclear cells of WT/WT mice compared to that of WT/CD23KO mice ([Fig. 4E1 and 4E2](#F4){ref-type="fig"}). In addition, airway function was assessed using whole body plethysmography. After OVA challenge, WT/WT and CD23KO/WT mice developed a significantly enhanced response to methacholine compared to WT/CD23KO chimeric mice ([Fig. 4F](#F4){ref-type="fig"}). As expected, saline-treated control animals displayed a decreased response to methacholine compared with WT/WT or CD23KO/WT mice, with a significant difference at \~50 mg/ml methacholine ([Fig. 4F](#F4){ref-type="fig"}).

Histopathological analysis of lung sections revealed remarkable structural changes in the lungs of WT/WT and CD23KO/WT mice ([Fig. 5](#F5){ref-type="fig"}). The semi-quantitative scoring of histological lesions confirmed that WT/WT and CD23KO/WT mice (mean score 3) had significantly more severe inflammation than WT/CD23KO mice (mean score 1). Lung sections of WT/WT and CD23KO/WT mice showed peribronchiolar and perivascular infiltrations of inflammatory cells ([Fig. 5A1 and 5A2](#F5){ref-type="fig"}) compared with WT/CD23KO ([Fig. 5A1 and 5A2](#F5){ref-type="fig"}) and control mice ([Fig. 5B](#F5){ref-type="fig"}). Deposition of collagen in connective tissue, detected with the Masson-Trichrome staining, was found surrounding the peribronchiolar epithelial cells in lung sections from WT/WT and CD23KO/WT mice, but not in WT/CD23KO mice ([Figure 5c](#F5){ref-type="fig"}). Furthermore, lung sections of WT/WT and CD23KO/WT mice, but not those of the WT/CD23KO mice, displayed significant increases in mucin-secreting goblet cells among the bronchial epithelial cells in response to OVA sensitization and challenge ([Fig. 5D1](#F5){ref-type="fig"}). Excessive mucus secretion from hyperplastic goblet cells is a feature of the asthmatic airway. Quantitative analysis confirmed that the numbers of goblet cells were significantly higher in WT/WT and CD23KO/WT mice than in WT/CD23KO mice ([Fig. 5D2](#F5){ref-type="fig"}). Taken together, these data suggest that CD23 in lung structural cells, and specifically in AECs, contributes to the early stages of allergic inflammation.

### Targeted blocking of CD23 in the airway attenuates allergic airway inflammation {#S7}

The data described above suggest that CD23 expressed in the airway, especially in epithelial cells, is likely to play a pivotal role in the initiation and propagation of allergic airway inflammation. We reasoned that targeting CD23 in the airway could be used as a means of therapeutic intervention against asthma development. To test this hypothesis, we used a receptor-blocking CD23 mAb that selectively binds to CD23 and prevents IgE or IC binding, consequently preventing or reducing the efficiency of the transcytosis of these molecules across the epithelial barrier ([@R16]). Using the same assay described above, we found that the mouse-specific anti-CD23 mAb, B3B4, was able to efficiently block IgE transcytosis across primary mouse tracheal epithelial cells *in vitro* ([Fig. 6A](#F6){ref-type="fig"}). Therefore, before OVA challenge, OVA-sensitized WT mice were i.n. treated with 75 µg B3B4 Ab or control rat IgG2a in PBS twice, once at 24 h before and then again 1 h before challenge. Five hours after challenge, a significant amount of OVA was detected in the sera of the control IgG2a-treated mice, but not in that from B3B4-treated animals ([Fig. 6B](#F6){ref-type="fig"}). These data indicate that B3B4 mAb is able to efficiently block CD23-mediated transcytosis of IgE and ICs. To determine whether B3B4 mAb-treated mice exhibited reduced inflammation, we first measured the levels of OVA-specific IgE, IL-13, and IL-5 in the sera or BAL fluid. Following OVA aerosol challenge, the levels of IgE, IL-13, and IL-5 were significantly lower in both BAL fluid and sera of B3B4-treated mice than in IgG2a-treated control mice ([Fig. 6C--6E](#F6){ref-type="fig"}). In addition, the numbers of CD45^+^ CD11bhi/int CD11c^−^ Siglec-F^+^ eosinophils in the BAL of B3B4-treated mice (3.74%) were significantly lower than those of control mice (6.4%) ([Fig. 6F1 and 6F2](#F6){ref-type="fig"}).

Histopathological analysis of lung sections revealed a remarkable difference between control and B3B4-treated mice in the pathology caused by inflammatory responses ([Fig. 7A1](#F7){ref-type="fig"}). The semi-quantitative scoring of histological lesions showed that IgG2a-treated control mice (mean score 3) had significantly more severe inflammation than B3B4-treated mice (mean score 1) ([Fig 7A2](#F7){ref-type="fig"}). Using Masson-Tricrome staining, we found an appreciable peribronchial fibrosis (blue) in the control, but not in B3B4-treated mice ([Fig. 7B](#F7){ref-type="fig"}). We used PAS (Periodic acid--Schiff) staining to further determine the extent of mucus cell hyperplasia. Our results showed a remarkable decrease in PAS-positive cells in the bronchial epithelium of B3B4-treated mice ([Fig. 7C1](#F7){ref-type="fig"}), when compared with IgG2a-treated control mice. Also, the percentage of PAS-positive cells in B3B4-treated mice was significantly lower than that in IgG2a-treated mice ([Fig. 7C2](#F7){ref-type="fig"}). Furthermore, B3B4-treated animals showed a significantly decreased response to methacholine compared to control treated mice ([Fig. 7D](#F7){ref-type="fig"}). Therefore, our results demonstrate that the *in vivo* treatment with CD23 blocking antibody not only interferes with the transcytosis function of epithelial CD23, but also confers effective protection against the development of allergic inflammation.

DISCUSSION {#S8}
==========

Asthma is a very heterogeneous and complex disease involving multiple pathways and cellular components in its pathogenesis ([@R21], [@R22]). The early response during airway allergy is strongly associated with inhaled allergens that can crosslink specific IgE molecules on the surface of immune cells, leading to their activation and release of primary inflammatory mediators by cells including T cells, mast cells, and basophils. ([@R1], [@R8], [@R21]). The late-phase reaction is characterized by recruitment and activation of leukocytes including lymphocytes, eosinophils, macrophages, and neutrophils, leading to bronchial or lung tissue infiltration ([@R1], [@R21], [@R22]). Additionally, the airway epithelium acts as a major barrier between the inhaled allergens and immune cells in the parenchyma ([@R23], [@R24]). Although CD23 is known to be expressed in human AECs ([@R16]), the role of airway epithelial CD23 in the development of allergic inflammation *in vivo* has remained relatively undefined.

Our previous study showed that CD23 is capable of transporting IgE and IgE-derived ICs across polarized human AECs *in vitro* ([@R16]). To extend upon this observation *in vivo*, we demonstrated that CD23 mRNA and protein are expressed in the AECs of mice and this receptor is responsible for transporting IgE and the ICs across the airway epithelium *in vivo*. Furthermore, this finding was confirmed by the failure of CD23 KO mice to transport IgE or ICs across AECs, and is further supported by the co-localization of CD23 with i.n. inoculated IgE and OVA in mouse AECs. A previous study suggested that intestinal epithelial cells can also express FcεRI by immunohistochemistry ([@R25]); however, we barely detected mouse FcεRI alpha chain in AECs using immunohistochemistry ([Fig. S11](#SD1){ref-type="supplementary-material"}), and therefore it is unlikely FcεRI contributes significantly to IgE transcytosis across the airway epithelium. In addition, mouse FcγRII, FcγRIII, and FcγRIV bind IgE or IgE immune complexes, but are expressed in macrophages or mast cells and not in AECs ([@R26], [@R27]). Although IgE is clearly detected in the sera of WT mice after i.n. inoculation, the serum concentration of IgE may not reflect the exact amounts of IgE transported by CD23, since IgE is cytophilic and much of it presumably remains in tissues. Thus, these *in vivo* results together with what is known of IgE transport in human AECs *in vitro* confirm that CD23 mediates transepithelial transport of IgE and the ICs across the airway mucosal barrier.

The major finding of this study is that epithelial CD23 plays a critical role in initiating and facilitating allergic airway inflammation. The airway epithelium acts as a barrier preventing allergens from penetrating into the airway parenchyma; however, we have shown a role for CD23 in the transepithelial transport of IgE and ICs *in vitro* ([@R16]) and *in vivo*. It is conceivable that transcytosed IgE-allergens engage immune cells leading to their activation and the release of various inflammatory and lipid mediators. In this study the major immune cell engaged is T cells, which are activated via antigen presentation by dendritic cells or basophils, since the OVA/alum sensitization and challenge mouse model used is T cell dependent. In a separate study, we are specifically testing the role of CD23-mediated IgE transport in activating mast cell degranulation through use of the mast cell/IgE-dependent mouse model ([@R28], [@R29]).

In addition, using OVA sensitization and aerosol challenge in bone-marrow chimeric mouse models, we clearly demonstrate a causal relationship between CD23 expression in airway structural cells, mainly epithelial cells and airway eosinophilia, and extensive lung damage and airway hyperactivity. There is ample evidence supporting our finding of a role for CD23 in this effect. First, CD23-mediated epithelial transcytosis of the ICs may protect allergens from degradation both by diverting allergens from lysosomal degradation ([@R30]) and by physical binding to IgE ICs. Consistent with this, we detected intact OVA antigen in the *in vitro* transcytosis as well as in WT mouse sera after i.n. inoculation ([@R16]). Consequently, larger quantities of allergens gain access to immune cells, which are activated through allergen crosslinking of FcεRI or antigen presentation. When administered through the airways, IgE ICs formed *in vitro* have been shown to be more potent than allergen alone at inducing airway inflammatory responses in sensitized mice ([@R31]). Second, in asthma patients both CD23 expression and IgE secretion into the airway have been shown to be enhanced ([@R32], [@R33]). Consistent with these results, we found that mouse CD23 expression is significantly increased in the AECs of sensitized mice. Indeed, IL-4 exposure upregulates CD23 expression and enhances the transcytosis of IgE or IgE IC across a polarized human airway epithelial monolayer ([@R16]). This suggests that CD23 is likely to play similar roles in promoting human asthma by transcytosing IgE and IgE-allergen complexes across the airway epithelial barrier. Third, following passive sensitization with OVA-specific IgE antibody, WT, but not CD23 KO mice produce significantly increased amounts of OVA-specific IgG and IgE after challenge ([@R18]). This result is likely due to CD23-mediated transport of IgE and the IgE-OVA immune complex across the airway epithelial barrier in WT mice. Therefore, there is abundant evidence for the involvement of CD23 expressed on structural cells in lung damage and airway hyperreactivity.

Several additional issues concerning the facilitation of airway allergic inflammation by CD23 should be considered. First, IgE-allergen ICs that can crosslink CD23 on AECs may initiate signaling cascades in epithelial cells contributing to the induction of pro-inflammatory cytokines and chemokines. Cytokines, in turn, cause increased CD23 expression and transcytosis of the ICs, which results in recruitment of more immune cells into the airways forming a positive feedback loop resulting in inflammation. Second, while use of chimeric mouse models allowed us to reconstitute CD23 expression in hematopoietic cells in CD23KO mice, CD23 is also expressed in structural cells in the lung including in airway smooth muscle cells, although its role in these cells remains unknown ([@R33]). Airway smooth muscle hyperplasia has been observed in asthmatic airways ([@R1], [@R21], [@R22]). Thus, we speculate that CD23 may work in these cells to induce signaling following engagement by IgE ICs. However, because FcεRI is also expressed in this cell type ([@R34]), it is possible these two receptors play redundant roles. Identification of the role of CD23 in smooth muscle cells will require further investigation. Third, in classic allergic mouse models multiple sensitizations and challenges with allergens may compromise or damage the airway epithelial barrier. Hence, in this study we reduced the number of challenges to a single dose and found this to be sufficient to induce appreciable allergic inflammation. However, use of this modified model may explain the relatively low eosinophil percentages in the BAL fluid in this study. Fourth, in our study a reciprocal chimeric mouse, CD23KO/WT, generated by transferring CD23KO bone marrow into irradiated WT recipients is used as a control. It has been suggested that CD23 KO mice develop enhanced allergic inflammation in the lung after sensitizations and challenges ([@R18]--[@R20]). In fact, in CD23 KO mice B lymphocytes do synthesize more allergen-specific IgE ([@R35]--[@R37]). Our results are in agreement with these findings although the intensity of lung inflammation seems to differ. Again, this may be due to the single dose challenge we utilized. Nonetheless, when expressed in different cell types, such as in epithelial cells versus B cells, CD23 may exert distinct effects on the development of allergic inflammation.

The capacity of CD23 to facilitate allergic inflammation in the airway epithelia may also have important implications for food allergies. In fact, expression of CD23 by intestinal epithelial cells of both humans and rodents has been shown ([@R30], [@R38]). Moreover, CD23 on the intestinal epithelium is capable of transporting IgE and ICs in both *in vitro* and in *ex vivo* models. Interestingly, IL-4 also enhances transcytosis of IgE and ICs in the intestinal epithelial monolayer. Previous studies have shown that the IgE-derived ICs in an *in vitro* cultured, human intestinal epithelial monolayer preferentially activate the MAPK pathway causing the subsequent release of chemokines IL-8 and CCL20 ([@R38]). This suggests CD23 is possibly involved in signaling leading to pro-inflammatory responses. However, there is no concrete evidence supporting the concept that CD23 in the intestinal epithelium is able to directly initiate or facilitate allergic inflammation caused by food *in vivo*.

Intravenous infusions of CD23-specific Ab has previously been proposed as a therapeutic strategy in asthma ([@R9], [@R38]). Since CD23 expressed in the airway epithelium is likely to play a pivotal role in the initiation and development of airway allergic inflammation, we sought to test whether targeting this molecule in the airway might be useful as an early therapeutic intervention during development of asthma. Using a sensitized mouse model, we demonstrated that CD23 mAb, when administered i.n. before challenge, effectively reduces the development of lung hypersensitivity. In a previous study we showed that human CD23-specific Ab or soluble CD23 could significantly reduce the efficiency of IgE or IC transcytosis across the human airway epithelial monolayer ([@R16]). We postulate that CD23 mAb selectively binds to epithelial CD23 preventing IgE or ICs from binding to CD23, and/or that CD23 mAb destabilizes the trimeric structure, which compromises CD23 affinity for IgE or enhances the sensitivity of CD23 to the cleavage by ADAM10 ([@R40]). Further study will be required in order to determine exactly which mechanisms are responsible. Nevertheless, without functional CD23 AECs are unable to capture allergens directly, thus preventing allergen transport across the epithelial barrier as well as the activation of immune cells by IgE-allergens and subsequent allergic/asthmatic symptoms.

Taken together, this study demonstrates that airway epithelial CD23 functions as a specific IgE or IC transporter *in vivo*. Our results allow us to propose a working model: allergen specific IgE secreted by plasma cells is transported by CD23 to the lumen of the airway where it captures inhaled allergens by forming ICs. CD23 then mediates apical to basal transcytosis of functional IgE-allergen ICs, which are capable of activating subepithelial immune effector cells, such as mast cells, basophils, and eosinophils for degranulation and dendritic cells for antigen presentation ([Fig. S12](#SD1){ref-type="supplementary-material"}). Moreover, cytokines secreted by activated immune cells may provide feedback to the airway epithelium to increase the expression of CD23 and to support the influx of a new wave of inflammatory and adaptive immune cells into the airway mucosa.

MATERIALS AND METHODS {#S9}
=====================

Antibodies, mice, cells and reagents {#S10}
------------------------------------

The murine lung epithelial cell line LA4 was a kind gift from Dr. Marc B. Hershenson (University of Michigan). The cells were cultured in Ham\'s F12K complete medium containing 15 % FBS, 1% L-glutamine, non-essential amino acids, 100 U/ml penicillin and 100 µg/ml streptomycin. The cells were grown in a humidified atmosphere at 37°C containing 5% CO2. Chicken ovalbumin (OVA, Grade V) was purchased from Sigma Aldrich (St. Louis, MO). The anti-murine CD23 antibody (Ab)-secreting hybridoma B3B4, rabbit anti-murine CD23 Ab, CD23 knockout (KO) mouse on a *Balb/c* background were from Novartis ([@R41]). Six- to eight-week-old inbred female *Balb/c* mice were purchased from the National Cancer Institute (Frederick, MD). All mice were bred and maintained in HEPA-filtered caging units. Animal experiments were approved by the Animal Care and Use Committee at the University of Maryland.

Mouse OVA specific IgE monoclonal antibody (mAb) was purchased from Bio X-cell (West Lebanon, NH). Rabbit anti-mouse IgE-HRP, normal rabbit IgG, mouse anti-chicken OVA mAb and FITC-conjugated pan anti-cytokeratin mAb were purchased from Sigma Aldrich (St Louis, Mo). Mouse anti-β-tubulin Ab was purchased from Developmental Studies Hybridoma Bank (The University of Iowa, Iowa City, IA). HRP-conjugated rabbit anti-mouse IgG was obtained from Pierce (Rockford, IL). FITC-conjugated polyclonal goat anti-mouse IgE and normal goat anti-mouse IgE antibody were obtained from Novus Biologicals (Littleton, CO). Alexa fluor 555-conjugated goat anti-rabbit or anti-mouse IgG and Alexa fluor 633-conjugated goat anti-rabbit IgG were purchased from Invitrogen. HRP-conjugated bovine anti-goat IgG Ab was from Santa Cruz Biotechnology (Santa Cruz, CA). FITC-conjugated rat anti-mouse B3B4 mAb and rat anti-mouse CD16/CD32 Ab, FITC-conjugated hamster anti-mouse CD11c, FITC-conjugated hamster IgG1, PE-conjugated rat anti-mouse Siglec-F, PE-conjugated rat IgG2a, APC-Cy7-conjugated rat anti-mouse CD45, APC-Cy7-conjugated rat IgG2b were obtained from BD Pharmingen (San Diego, CA). APC-conjugated rat anti-mouse CD45R (B220) and FITC-conjugated rat IgG2a Ab were obtained from Caltag Laboratories. APC-conjugated rat anti-mouse CD11b and APC-conjugated rat IgG2b were obtained from Biolegend (San Diego, CA). Biotin-labeled mouse OVA specific IgE Ab was generated by EZ-Link Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL) following manufacturer's instruction. Recombinant murine IL-4 was from R&D Systems (Minneapolis, MN). Proteinase inhibitor cocktail was purchased from Calbiochem (San Diego, CA).

RT-PCR {#S11}
------

Semi-quantitative RT-PCR was performed on total RNA extracted from lung epithelial cell line LA4 as previously described ([@R16]). Total RNA was isolated from 2 × 10^6^/ml LA4 cells either mock stimulated or stimulated with murine IL-4 (20 ng/ml) using TRIzol reagents (Invitrogen) according to the manufacturer's instruction. One-step RT-PCR kit (Qiagen) was used to perform semi-quantitative RT-PCR. Negative control was performed without addition of RNA template. Primers used for amplification of murine CD23*a*, CD23*b* and murine CD23bΔ5 lacking exon 5 ([@R17]) were described previously. Primers used for the amplification of gylceraldehyde-3-phosphate dehydrogenase (GAPDH) were 5'-ACC CAG AAG ACT GTG GAT GG −3' and 5'-CAC ATT GGG GGT AGG AAC AC-3'. Amplification of CD23 mRNA and GAPDH was performed with 450 ng of total RNA in 20-µl volume. One step RT-PCR amplification consisted of reverse transcription at 50°C for 30 min, initial PCR activation at 95°C for 15 min, followed by PCR cycle of denaturation at 94°C for 1 min, annealing at 60°C for 1 min, extension at 72°C for 2 min for 40 cycles and a final extension at 72°C for 10 min. Annealing temperature for GAPDH was 55°C for 1 min and the rest of the amplification conditions was same. RT-PCR products were analyzed by resolving on 1.5 % agarose gel and DNA visualized by ethidium bromide staining. Semi-quantitative analysis of CD23 band intensities of RT-PCR products normalized to GAPDH values were analyzed by densitometry using Adobe Photoshop.

Genotyping of CD23 knockout (KO) mice {#S12}
-------------------------------------

Genotyping of the CD23 KO mice was performed with genomic DNA isolated from mouse tail using Puregene DNA isolation kit (Qiagen) following manufacturer's protocol. Primers used for genotyping were previously described ([@R41]). PCR amplification cycle consisted of initial PCR activation at 94°C for 3 min, followed by PCR cycle of denaturation at 94°C for 30 sec, annealing at 63°C for 1 min, extension at 72°C for 2 min for 35 cycles and final extension at 72°C for 10 min. PCR products were analyzed by resolving on 1.5 % agarose gel and DNA bands were visualized by ethidium bromide staining.

SDS-PAGE and Western blotting {#S13}
-----------------------------

SDS-PAGE and Western blot were performed as described previously ([@R16]). Protein concentrations of cell lysates were determined by Bradford method. The cell lysates were resolved on 12% SDS-PAGE gel electrophoresis under reducing conditions. Proteins were transferred onto a nitrocellulose membrane (Schleicher & Schuell) and the membrane was blocked with 5% skim milk in PBS. The membranes were probed separately with rat anti-mouse CD23 mAb B3B4 or murine anti-β-tubulin Ab for 1 h at room temperature or overnight at 4°C and then incubated with HRP-conjugated rabbit anti-rat Ab or HRP-conjugated rabbit anti-mouse Ab. All blocking, incubation, and washing procedures were performed in PBST solution (PBS and 0.05% Tween 20). Proteins were visualized using ECL method (Pierce).

Preparation of primary bronchoalveolar, tracheal epithelial and lung mononuclear cells {#S14}
--------------------------------------------------------------------------------------

The bronchoalveolar epithelial cells were isolated as previously described ([@R42]). The tracheal epithelial cells were isolated by following the procedures as described previously ([@R43]). The lung mononuclear cells were isolated by following the protocol as described previously ([@R44]). Briefly, the bronchoalveolar, tracheal epithelial cells and lung mononuclear cells were isolated by enzymatic digestion of lung with dispase (2.4 units/ml in DMEM), trachea with pronase (1.5 mg/ml in Ham\'s F-12 pen-strep) and lung with collagenase type 4 (1.25 mg/ml in RPMI 1640 medium) and the remaining procedures were performed as described previously ([@R42]--[@R44]).

Immunohistochemistry {#S15}
--------------------

Immunohistochemistry was performed as previously described ([@R15]). Mouse lung and trachea were inflated and embedded with Tissue-Tek OCT medium purchased from Sakura (Torrance, CA) and cryosectioned at 5 µM. The tissue sections were fixed and permeabilized with ice-cold acetone for 20 min and blocked with 10% normal goat serum (NGS) for 1 h at room temperature. Tissue sections were incubated with affinity-purified rabbit anti-mouse CD23 Ab, FITC-conjugated pan-cytokeratin Ab, FITC-conjugated goat-anti mouse IgE Ab or mouse anti-chicken OVA Ab in a humidified chamber overnight at 4°C followed by Alexa-fluor 555-conjugated goat anti-mouse Ab or Alexa fluor 555- or 633-conjugated goat anti-rabbit Ab. All incubations were performed with 3% NGS and finally nuclei were counterstained with DAPI (0.5 g/ml, Molecular Probes) in PBS. Negative controls were performed by incubating the isotype-matched mouse or normal rabbit IgG as primary Ab. Cover slips were mounted on the tissue sections with Prolong antifade reagent (Molecular probes, Invitrogen) and visualized and images were taken using Zeiss LSM510 laser scanning confocal microscope (Zeiss Microimaging Inc., NY). Images were processed by Zen 2007 software and Adobe Photoshop.

In vitro and in vivo transcytosis {#S16}
---------------------------------

In vitro transcytosis was performed as previously described with modifications ([@R16]). Tracheal epithelial cells from WT or CD23 KO mice were grown onto 0.4-µm-pore size Transwell inserts (BD Biosciences) to form a monolayer exhibiting transepithelial electrical resistances (1500 Ω/cm2). TER was measured using a tissue-resistance measurement equipped with planar electrodes (World Precision Instruments, Sarasota, FL). Monolayers were equilibrated in serum-free DMEM. Mouse IgE was added to either the apical (50 µg/250 µl) or the basolateral (50 µg/500 µl) side. They were incubated at 37°C for 2 h. For negative control, monolayers were also incubated at 4°C for 1 h before transcytosis. The media from the opposite chambers were collected and IgE was measured by ELISA.

In-vivo transcytosis was performed with a set of WT and CD23 KO mice. Mouse OVA specific IgE (50 µg/40µl) in PBS was given either intranasally (i.n.) or intraperitoneally (i.p.). 4, 8 or 24 h later, serum or bronchoalveolar lavage (BAL) fluids were sampled, respectively. Immune complexes (ICs) formed with mouse OVA specific IgE (20 µg) and chicken OVA (10 µg/40 µl) in PBS for 30 min at room temperature. Mice were i.n. inoculated with ICs or chicken OVA antigen alone (10 µg/40 µl) in PBS; 8 h later, sera were sampled. The concentration of OVA-specific IgE and OVA were determined by ELISA.

Enzyme-linked immunosorbent assay (ELISA) {#S17}
-----------------------------------------

The OVA-specific IgE and OVA concentrations were measured with ELISA. ELISA plates (Nunc) were coated overnight at 4°C with rabbit anti-chicken OVA Ab (10 µg/ml) for detecting OVA or with chicken OVA (10 µg/ml) for detecting OVA-specific IgE Ab. Plates were then washed three times with PBST (0.05% tween- 20 in PBS) and blocked with 10 % FBS in PBS for 1 h at room temperature. IgE or OVA diluted in 10% FBS with PBS was used as a standard. Biotinylated anti-mouse IgE Ab (1:500, OptEIA mouse IgE ELISA kit, BD) and HRP-conjugated streptavidin (1:250, OptEIA mouse IgE ELISA kit, BD) were used for detection of mouse IgE Ab. For detection of chicken OVA, biotinylated mouse OVA specific IgE (1:10,000) and HRP-conjugated streptavidin (1:250, BD) were used. Total IgE was determined by using OptEIA mouse IgE ELISA kit following manufacturer's protocol (BD). The readout was done using Victor III microplate reader (Perkin Elmer). The concentrations of mouse IL-4 and IL-5 (ELISA kit from BD Pharmingen, San Diego, CA) and IL-13 (ELISA kit from eBioscience, San Diego, CA) were measured using manufacturer's protocols.

Generation of bone-marrow chimeric mouse {#S18}
----------------------------------------

Six to eight weeks old WT or CD23 KO mice on *Balb/c* background were irradiated with 8 Gy (USDA ARS, Beltsville, MD) and repopulated intravenously with 5 × 10^6^ bone marrow cells from WT or CD23 KO mouse. The irradiated recipient mice were maintained on antibiotic-water for 2 weeks. Repopulated cells in the recipient mice, WT/WT (irradiated WT mice infused with WT cells), WT/CD23KO (irradiated CD23KO mice infused with WT cells), and CD23KO/WT (irradiated WT mice infused with CD23KO cells) were determined 4 or 8 weeks later by analyzing CD23 expression in the B cells, total T cells in spleen, bone marrow, and lung mononuclear cells by flow cytometry.

Flow cytometry {#S19}
--------------

Flow cytometry was used for analyzing surface expression of CD23 on the splenic B and T cells isolated from WT, CD23 KO, and chimeric mice. The CD11b^+/−^, CD45, CD11c and Siglec-F^+/−^ cells in the BAL or lung mononuclear cells were also analyzed. In brief, 1 × 10^6^ spleen cells, 1 × 10^6^ lung mononuclear cells or 1 × 10^5^ BAL cells (pooled from 5 mice) were washed with FACS washing buffer (2% FBS in PBS) and followed by blocking mouse Fc binding with CD16--CD32 mAb (BD) on ice for 30 min. The cell suspensions were respectively incubated with murine FITC-conjugated anti-CD23 B3B4 mAb, FITC-conjugated rat IgG2a, APC-Cy7-conjugated anti-B220 Ab, APC-Cy7-conjugated rat IgG2a Ab, FITC-conjugated hamster anti-mouse CD11c, PE\--conjugated rat anti-mouse Siglec-F, FITC-conjugated hamster IgG1, PE-conjugated rat IgG2a, APC-conjugated rat anti-mouse CD11b, APC-conjugated rat IgG2b, APC-Cy7-conjugated rat anti-mouse CD45, APC-Cy7-conjugated rat IgG2b for 30 min at 4°C, then washed and analyzed using a FACSAria II and the software FlowJo.

Mouse sensitization and challenge {#S20}
---------------------------------

Groups of WT, WT/WT, CD23KO/WT, and WT/CD23KO mice were sensitized with OVA by mixing with alum and given intraperitoneally (i.p.). Sterile PBS was used as a placebo control. Mice were sensitized by i.p. injection of 100 µg OVA emulsified in 4 mg aluminum hydroxide (AlumInject; Pierce Chemical, Rockford, IL) in a total volume of 100 µl on day 1, followed by 100 µg OVA on day 7 and 14. Mice were then challenged via the airways with nebulized OVA (1% in PBS) or PBS for 30 min on day 21. On day 22, AHR was measured. On day 22 or 23, the mice were sacrificed to collect BAL fluid, serum, and lung tissue for histopathology staining. For B3B4 antibody blocking experiment, the OVA sensitized WT mice received 75 µg of B3B4 or rat IgG2a intranasally after light anaesthetization with avertin (i.p.) on day 20 and day 21 before challenge. One hour later after second treatment, the Ab treated mice were challenged. On day 22, AHR was measured and on day 23, the mice were sacrificed to collect BAL fluid, serum, and lung tissue for histopathology staining. BAL fluid was subjected to cytospin, staining with modified Wright-Giemsa stain (Sigma), and differential counting of cells.

Measurement of AHR {#S21}
------------------

AHR was measured 24 h after OVA challenge in conscious, unrestrained, ventilated mice by whole-body plethysmograph (EMKA Technologies, Paris, France) as previously described ([@R45]). In comparison with invasive method, we elect to use noninvasive method to measure the dynamical changes in inflammatory responses. Briefly, mice were first exposed to nebulized physiologic saline for 3 min and then exposed to increasing concentrations of nebulized β-methacholine (Sigma) (3--100 mg/mL) by use of an ultrasonic nebulizer. Measurements were obtained for 3 min after the completion of each nebulization. Penh values measured during this period were averaged and expressed as absolute Penh values.

Histopathology {#S22}
--------------

Mice were euthanized and lungs were fixed immediately in 10% buffered formalin. The fixed tissues were embedded in paraffin, sectioned and stained with Haematoxylin and Eosin (H&E). The stained sections were examined under light microscope (Carl Zeiss, NY) and pathological lesions were recorded. The lesions of the lungs were scored from 0 to 3, on the basis of severity of cellular infiltration and structural alterations in pulmonary airways as follows; no lesions (score 0), mild peri-bronchiolar inflammation (score 1), moderate peri-bronchiolar inflammation and bronchiolar wall thickening (score 2), and severe peri-bronchiolar inflammation and bronchiolar wall thickening (score 3). The semi-quantitative measurements of lung inflammations was based on the scores above. The adjacent sections were processed for Periodic Acid-Schiff (PAS) staining for demonstration of mucus secreting goblet cells and Masson-Trichrome staining for demonstration of collagen deposition in the bronchiolar wall.

Statistics {#S23}
----------

The statistical difference between groups was tested by Student *t* test. A *P* value of less than 0.05 was considered significant. Data are expressed as mean ± SD.
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![Expression of CD23 in mouse AECs\
Cell lysates (50 µg) derived from primary nasal (**A**), tracheal (**B**), and lung (**B**) epithelial cells were electrophoresed on a 12 % SDS-PAGE gel under reducing condition. The separated proteins were transferred onto a nitrocellulose membrane, blotted with rat anti-mouse CD23 mAb (B3B4) followed by HRP-conjugated rabbit anti-rat IgG Ab. Proteins were visualized using the ECL method. Lysates (50 µg) from mouse spleen or CHO cells were used as a positive or negative control, respectively. β-tubulin was used as an internal control. Arrows indicate mouse CD23 and β-tubulin. (**C**) Immunohistochemical staining of mouse lung. Normal mouse lung was prepared in OCT medium and cryosectioned at 5 µm. Frozen tissue sections were fixed and permeabilized with ice-cold acetone and blocked with 10% normal goat serum. A spleen section was used as a positive control. Sections were incubated with rabbit anti-CD23 Ab or normal rabbit IgG, followed by staining with Alexa Fluor 555-conjugated goat anti-rabbit Ab. Nuclei were stained with DAPI. Images were captured using a Zeiss LSM510 confocal microscope. Samples were visualized under consisten contrast and brightness settings.](nihms661943f1){#F1}

![CD23-mediated transcytosis of IgE across mouse epithelial monolayers\
**A.** Transcytosis of mouse IgE in primary mouse tracheal epithelial cells (TEC). TEC isolated from WT or CD23 KO mice were grown on transwell filters and cells were allowed to become polarized. Mouse IgE was added to the apical *(top panel)* or basolateral *(lower panel)* chambers and incubated at 37°C for 2 h. The medium from opposite chamber was collected and IgE concentration was measured by ELISA. A: Apical; BL: Basolateral. \*P\<0.05.\
**B.** Airway transcytosis of mouse IgE in wild type (WT) or CD23 KO mice. *Top Panel*: OVA-specific IgE (40 µg) was i.n. inoculated into either WT or CD23 KO mice for 5 min. Sterile PBS was used as a control. Sera were collected at indicated time points. *Bottom Panel*: OVA-specific IgE (40 µg) or sterile PBS was i.p. inoculated into either WT or CD23 KO mice. BAL fluid was collected 8 h after injection. OVA-specific IgE was measured in the sera and BAL fluid by ELISA. \*P\<0.05.\
**C.** Colocalization of CD23 and IgE in mouse trachea. Naive mice were anaesthetized with avertin and 20 µg of mouse IgE or PBS was i.n. inoculated. Mice were sacrificed 20 min after treatment, and the trachea was collected and snap frozen in OCT medium and cryosectioned at 5 µm. Frozen tissue sections were fixed and permeabilized with ice-cold acetone and blocked with 10% normal goat serum (NGS). Sections were incubated with rabbit anti-CD23 Ab followed by staining with Alexa Fluor 555-conjugated goat anti-rabbit Ab (red) and FITC-conjugated goat anti-mouse IgE Ab (green). Lung epithelial cells did not stain positive with rabbit anti-IgE Ab. Images were captured using a LSM510 confocal microscope. Samples were visualized under consistent contrast and brightness settings. Arrows indicate IgE Ab transported into the parenchyma.](nihms661943f2){#F2}

![CD23-mediated transcytosis of OVA-IgE immune complexes (ICs) across mouse epithelial monolayers\
**(A)**. Apical to basolateral transcytosis of ICs in naive mice. ICs were formed with 20 µg OVA-specific IgE and 10 µg of OVA at room temperature for 30 min. WT or CD23 KO mice were anaesthetized with avertin and ICs, 10µg OVA, or PBS was i.n. inoculated, respectively. Sera were collected 8 h later and OVA antigen quantitated by ELISA. \*P\<0.05.\
**(B)**. Colocalization of CD23 and ICs in the lungs of naïve mice. OVA-IgE ICs or PBS were i.n. inoculated into anaesthetized mice, which were sacrificed 20 min later and lung tissue was prepared in OCT medium and cryosectioned at 5 µm. Frozen sections were fixed and permeabilized with ice-cold acetone and blocked with 10% NGS. Sections were incubated with rabbit anti-CD23 Ab or mouse anti-chicken OVA Ab followed by staining with Alexa fluor 633-conjugated goat anti-rabbit Ab, Alexa fluor 555-conjugated goat anti-mouse Ab, and FITC conjugated goat anti-mouse IgE Ab. Nuclei were stained with DAPI and sections were imaged using a LSM510 confocal microscope. Samples were visualized under consistent contrast and brightness settings. Arrows indicate the colocalization (white).](nihms661943f3){#F3}

![Epithelial CD23 facilitates airway inflammation after OVA sensitization and challenge in chimeric mice\
**A.** Mice were sensitized (i.p.) with OVA or left untreated. Lung and trachea epithelial cells were isolated and cell lysates (50 µg) were subjected to 12 % SDS-PAGE gel electrophoresis under reducing conditions. Proteins were transferred onto nitrocellulose membranes and blotted with rat-anti mouse CD23 mAb (B3B4) followed by HRP-conjugated rabbit anti-rat IgG Ab. Proteins were visualized using ECL. Arrows indicate mouse CD23 and β-tubulin.\
**B--D.** WT/WT, CD23KO/WT, WT/CD23KO chimeric mice were i.p. sensitized with 100 µg OVA plus 4 mg alum at day 0 and subsequently injected (i.p.) with 100 µg OVA on day 7 and 14. Mice were challenged on day 21 with nebulized 1 % OVA for 30 min. 5 h after OVA challenge, sera were collected and OVA quantitated by ELISA (B). 24 h after OVA challenge, BAL fluid and sera were collected and OVA-specific IgE (C) and IL-4 (D) concentrations assessed by ELISA. \*P\<0.05.\
**E.** Flow cytometric analysis of eosinophils in BAL fluid. Chimeric mice were sensitized with OVA and received a single aerosol OVA challenge. Total leukocytes obtained from BAL fluid were gated on CD45^+^ CD11b^hi/int^ and mononuclear cells obtained from lung were gated on CD45^+^ CD11b^hi^ cells and further analyzed for CD11c and Siglec-F expression (E1). The mean percentage of eosinophils in BAL fluid from three different experiments was calculated (E2). \*P\<0.05.\
**F. Airway responsiveness to methacholine (MCh) in chimeric and control mice**. WT/WT, CD23KO/WT, and WT/CD23KO chimeric mice were sensitized (i.p.) with OVA and received a single aerosol challenge with OVA while control mice were sensitized and received a single aerosol challenge with PBS. Airway resistance was measured 24 h after challenge. First, the baseline and resistance against PBS challenge were measured followed by generation of a dose-response curve against an increasing concentration of nebulized MCh (3--100 mg/ml). \*P\<0.05.](nihms661943f4){#F4}

![Effects of epithelial CD23 on pathological changes in lung\
WT/WT, CD23KO/WT, and WT/CD23KO chimeric mice were sensitized with OVA and received a single aerosol OVA challenge. Lung tissues were fixed in formalin and embedded in paraffin 24 h after OVA challenge.\
**A.** Lung tissue section were stained with H&E and examined by light microscopy at the indicated magnifications. Lung sections from WT/CD23KO chimeric mice (top right) showed a significant attenuation of inflammation compared with that from WT/WT (top left) and CD23KO/WT (top middle) mice. Insets (top, green squares) are shown at a higher amplification (arrow). Pronounced alveolar and bronchiolar changes are shown in WT/WT or CD23KO/WT mice. Semi-quantitation of inflammation by histological analysis (A2). \*P\<0.05. Lung sections from either CD23 KO or WT mice are shown in panel (B).\
**C.** Lung sections were stained using the Masson\'s trichrome method. WT/CD23KO chimeric mice showed significantly decreased peribronchial fibrosis (blue) in the lung compared with WT/WT or CD23KO/WT chimeric mice. Data are representative of two independent experiments.\
**D.** Lung sections were stained with PAS. WT/CD23 KO chimeric mice showed a significant reduction in goblet-cell hyperplasia (arrows) in the lung bronchial area (*top panel*) in comparison with that of WT/WT or CD23KO/WT chimeric mice (D1). Goblet cells were counted and the mean percentage of three different sections is indicated (D2). \*P\<0.05.](nihms661943f5){#F5}

![Effect of B3B4 Ab targeting of airway CD23 on IgE and allergen transcytosis, inflammatory cytokine production, and eosinophil infiltration\
**A.** B3B4 Ab blocked IgE transcytosis in primary mouse TEC. Cells were isolated from WT mice, grown on transwell filters, and allowed to polarized. Purified B3B4 Ab or rat IgG2a (50 µg/ml) was added into the apical chamber for 45 min at 4°C to allow Ab binding to apical CD23. Mouse IgE was then added to apical chambers and incubated at 37°C for 2 h. Medium from the basolateral chamber was collected and IgE content measured by ELISA. \*P\<0.05.\
**B--F.** Sensitization of mice with OVA. Before challenge, OVA-sensitized WT mice received i.n. inoculation with 75 µg B3B4 Ab or rat IgG2a in PBS twice, once at 24 h before, and again 1 h before, challenge. Sera were collected 5 h after the single OVA challenge and OVA in sera was quantified by ELISA (B). BAL fluid or sera were collected 48 h after OVA challenge. Concentrations of OVA-specific IgE (C), IL-13 (D), and IL-5 (E) in either BAL fluid or sera were measured by ELISA. Eosinophils were assessed by flow cytometric analysis of CD45^+^ CD11b^hi/int^ CD11c^−^ Siglec-F^+^ cells in BAL fluid. The mean percentage of the eosinophils in the BAL fluid from three different experiments was calculated (F2). \*P\<0.05.](nihms661943f6){#F6}

![Effect of B3B4 Ab targeting of airway CD23 on airway allergic inflammation\
WT mice were sensitized with OVA and received i.n. inoculation of 75 µg B3B4 Ab or rat IgG2a in PBS twice, once at 24 h before and again 1 h before challenge. Subsequently, mice were challenged with OVA and 24 h later AHR was measured, and 48 h later mice were sacrificed and lung tissues were fixed in formalin and embedded in paraffin.\
**A.** Lung sections were stained with H&E and examined by light microscopy at the indicated magnifications. Lung sections in B3B4 Ab-treated mice showed significant attenuation of inflammation in comparison with that of control rat IgG2a-treated mice. Insets (green squares) are shown at higher amplifications. Semi-quantitative assessment of inflammation in histological sections was analyzed (A2 panel). \*P\<0.05.\
**B.** Lung tissue sections were stained using the Masson\'s trichrome method. B3B4 Ab-treated mice showed significantly decreased peribronchial fibrosis (blue) in the lung compared with control Ab-treated mice.\
**C.** Lung tissue sections were stained with PAS. B3B4-treated mice had a significant reduction in goblet-cell hyperplasia in the lung bronchial area compared with that of the rat IgG2a-treated mice (c1). Goblet cells were counted and the mean percentage of three different sections is presented (c2). \*P\<0.01.\
**D.** Airway responsiveness to methacholine (MCh) in B3B4 Ab-treated mice. AHR was measured 24 h after a single OVA challenge. First, baseline airway resistance and resistance against PBS challenge were measured and then a dose response curve against increasing concentrations of nebulized MCh (3--100 mg/ml) was generated. \*P\<0.05.](nihms661943f7){#F7}
